- Home
- ACXP vs INDP Comparison
ACXP vs INDP Comparison
Compare ACXP & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- INDP
- Stock Information
- Founded
- ACXP 2017
- INDP 2000
- Country
- ACXP United States
- INDP United States
- Employees
- ACXP N/A
- INDP N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- INDP Health Care
- Exchange
- ACXP Nasdaq
- INDP Nasdaq
- Market Cap
- ACXP 9.0M
- INDP 8.8M
- IPO Year
- ACXP 2021
- INDP N/A
- Fundamental
- Price
- ACXP $0.32
- INDP $0.46
- Analyst Decision
- ACXP Strong Buy
- INDP Strong Buy
- Analyst Count
- ACXP 1
- INDP 2
- Target Price
- ACXP $12.00
- INDP $8.50
- AVG Volume (30 Days)
- ACXP 190.7K
- INDP 1.2M
- Earning Date
- ACXP 05-13-2025
- INDP 05-07-2025
- Dividend Yield
- ACXP N/A
- INDP N/A
- EPS Growth
- ACXP N/A
- INDP N/A
- EPS
- ACXP N/A
- INDP N/A
- Revenue
- ACXP N/A
- INDP N/A
- Revenue This Year
- ACXP N/A
- INDP N/A
- Revenue Next Year
- ACXP N/A
- INDP N/A
- P/E Ratio
- ACXP N/A
- INDP N/A
- Revenue Growth
- ACXP N/A
- INDP N/A
- 52 Week Low
- ACXP $0.32
- INDP $0.46
- 52 Week High
- ACXP $3.33
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- ACXP 23.06
- INDP 22.38
- Support Level
- ACXP $0.40
- INDP $0.58
- Resistance Level
- ACXP $0.45
- INDP $0.56
- Average True Range (ATR)
- ACXP 0.03
- INDP 0.14
- MACD
- ACXP 0.00
- INDP -0.03
- Stochastic Oscillator
- ACXP 0.00
- INDP 0.54
Stock Price Comparison Chart: ACXP vs INDP
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.